A familial Alzheimer's genetic panel tests for mutations in APP, PSEN1, or PSEN2 — three genes that cause early-onset familial Alzheimer's disease (EOFAD), an inherited form that typically starts before age 65, according to clinical genetic-testing medical policy. Before ordering one, an adult over 65 needs to ask whether their family history actually fits what the panel looks for, what a result would and wouldn't tell them, and whether a different test answers their real question instead. The most important question comes first: does this panel even apply to someone past 65? The genes it covers cause a rare, inherited pattern of disease, not the common form of Alzheimer's that shows up later in life. Getting that distinction wrong before testing can lead to a result that explains nothing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Does my family history match what this panel tests for?
- What will a positive or negative result actually tell me?
- Is APOE testing a different question than I'm asking?
- Could a treatment decision be the real reason to test?
- Questions worth bringing to a genetic counselor
- Frequently Asked Questions
Does my family history match what this panel tests for?
PSEN1, PSEN2, and APP mutations are passed down in an autosomal dominant pattern, meaning a parent with the mutation has roughly a 50% chance of passing it to each child, and the disease they cause shows up early — usually well before age 65, per the same clinical genetic-testing medical policy. Insurers' clinical criteria restrict this panel to people with a family history of apparent autosomal-dominant early-onset Alzheimer's, a first-degree relative with a known mutation in one of these genes, or a symptomatic early-onset person whose family history is unknown, such as someone who was adopted — not to asymptomatic adults over 65 with no such pattern, according to Blue Cross NC's policy.
A reader whose parent or sibling developed Alzheimer's in their 70s or 80s, with no other early-onset cases in the family, is describing the common late-onset form, not the pattern this panel is built to catch. Ask whether anyone in the family was diagnosed before 65, and whether that pattern repeated across generations, before requesting PSEN1, PSEN2, or APP testing.
What will a positive or negative result actually tell me?
Even within families that do have the early-onset pattern, the panel does not explain every case. Among 65 early-onset Alzheimer's families studied, 66% of cases traced to PSEN1 mutations and 16% to APP mutations, while 18% remained genetically unexplained, according to a Journal of Medical Genetics study.
A negative result in a family with a clear inherited pattern does not rule out an inherited cause — it may mean the mutation lies outside the three genes tested. Detection rates vary by gene: molecular panel testing finds a PSEN1 mutation in roughly 30-70% of EOFAD cases tested, an APP mutation in about 10-15%, and a PSEN2 mutation in fewer than 5%, per Excellus BlueCross BlueShield's medical policy. That same policy notes a positive result does not predict age of onset, severity, or how fast the disease will progress — it confirms a cause, not a timeline.
Is APOE testing a different question than I'm asking?
Some readers over 65 are really asking about risk for the common, late-onset form of Alzheimer's rather than the rare inherited form. That risk is linked to APOE-e4, a gene variant on chromosome 19, which is the only confirmed genetic risk factor for late-onset Alzheimer's — the form seen in most people over 65 — but it raises risk rather than causing the disease directly, unlike PSEN1, PSEN2, or APP, according to a PMC-indexed review.
A National Institute on Aging/Alzheimer's Association working group concluded that APOE genotyping's usefulness for predicting Alzheimer's risk in people without symptoms has not been established in longitudinal population studies, and the group did not recommend it for that purpose, as reported by The Gray Sheet. A 2011 joint practice guideline from the National Society of Genetic Counselors and the American College of Medical Genetics recommends against routine clinical APOE testing outside formal genetic counseling, and as of a 2025 conference abstract, that guidance still stands while an update is in progress but not yet published, per the Alzheimer's Association International Conference abstract. Ask a genetic counselor directly whether APOE testing or the familial panel matches the question being asked, since the two serve different purposes.
Could a treatment decision be the real reason to test?
There is one circumstance where APOE testing applies squarely to someone over 65 outside the classic familial pattern: starting an anti-amyloid drug. APOE-e4 carriers, especially those with two copies, face a higher rate of amyloid-related imaging abnormalities (ARIA) — brain swelling or bleeding detectable on imaging — when taking anti-amyloid drugs like lecanemab, which is why FDA labeling now calls for APOE genotype testing before starting such treatment, according to the Alzheimer's Association International Conference abstract.
The consequences can be concrete: the UK product label for lecanemab restricts its use to adults who are APOE4 heterozygous carriers or non-carriers, excluding people with two copies of APOE-e4 because of their elevated ARIA risk, per the UK Clinical Pharmacy pharmacogenomics handbook. Before agreeing to APOE testing in this context, ask the prescriber how the result would change the treatment plan, and whether a homozygous e4/e4 result would take a specific drug off the table.
Questions worth bringing to a genetic counselor
A short list to work through before any sample is drawn: A genetic counselor can match the right test to the right question before a result arrives that answers something the reader never meant to ask.
- What pattern of diagnosis ages shows up across my family — mostly before 65, or mostly after?
- Am I asking about a rare inherited cause (PSEN1/PSEN2/APP) or a risk factor for the common late-onset form (APOE)?
- If my result is negative, does that rule out an inherited cause in my family, or just these three genes?
- If my result is positive for APOE-e4, does that change what treatments I'm eligible for, rather than just my risk estimate?
- Is this test being ordered to answer a diagnostic question, or to clear me for a specific drug like lecanemab?
Frequently Asked Questions
Can someone over 65 still carry a PSEN1, PSEN2, or APP mutation?
Yes, but these mutations typically cause disease onset before 65, so a diagnosis after that age in a family with no early-onset pattern points away from these genes, per the clinical genetic-testing medical policy.
If my APOE result comes back e4/e4, does that mean I will get Alzheimer's?
No. APOE-e4 is a risk modifier for late-onset Alzheimer's, not a deterministic cause like the familial-panel genes, according to the PMC-indexed review.
Why would a doctor order APOE testing if it isn't recommended for predicting risk?
The main accepted use at this point is screening before anti-amyloid treatment, since APOE-e4 carriers face higher rates of ARIA on drugs like lecanemab, per the Alzheimer's Association International Conference abstract.
